FSL 1

Research use only, not for human use.

TLR2/6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.

TLR2/6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.

FSL-1 significantly reduces HSV-2 replication in vitro. FSL-1 reduces HSV-2 replication in human vaginal epithelial cells (EC).FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile.FSL-1 enhances phagocytosis of bacteria by macrophages through a Toll-like receptor 2-mediated signalling pathway. Cell Viability Assay Cell Line:V11I, V12I or V19I immortalized human vaginal EC Concentration:6 μg or 0.1 μg Incubation Time:Added at 24, 6 or just prior to HSV-2 inoculation (104pfu/well) Result:The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.

——

——

GPCR/G Protein

Antibacterial

——

——

——

322455-70-9

1666.16

C84H140N14O18S

>98% (HPLC)

water:2 mg/mL

CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)N)OC(=O)CCCCCCCCCCCCCCC

——

(-20℃)

With Ice Pack

≥ 2 years